Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

COVID-19 2Severe Acute Respiratory Syndrome 1Neoplasms 1Mastocytosis 1Hypersensitivity 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × BNT162 Vaccine × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

NCT05016622 2024-07-31

Booster Dose Trial

Montefiore Medical Center

Phase 2 Terminated
106 enrolled 39 charts

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡